Vision & strategy

Ambrilia Biopharma is dedicated to identifying and developing innovative, safe and effective therapies that address unmet medical needs in the fields of oncology and infectious diseases. Ambrilia strives to improve the quality of existing medicines while developing novel therapeutics for the benefit of patients suffering from cancer and infectious diseases.  

Ambrilia’s strategy is to discover or acquire and advance drug candidates through early to mid-stage clinical trials and then pursue co-development or out-licensing options with pharmaceutical companies. At the same time, Ambrilia is developing and manufacturing improved formulations of existing drugs in order to provide the Company with an early and sustainable cash flow.

History

Ambrilia Biopharma was created pursuant to the merger via acquisition of Procyon Biopharma, a publicly-traded Montreal-based biotechnology company that was developping innovative therapeutics in the fields of oncology and HIV/AIDS, with Cellpep S.A., a French private biotechnology that was developping therapeutics in oncology and infectious diseases. The merger, along with a concomitant $18.1 million financing was completed on March 1, 2006.

 

Documentation

Financial Reports